Organization (Industry)
Encore Medical, Inc.
ClinicalTrials.gov lists Encore Medical, Inc. as lead sponsor of 22 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Encore Medical, Inc.: 22 lead-sponsored trials and 1 legal-entity registration.
Disease areas (15)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Osteoarthritis | 12 |
| Arthritis, Rheumatoid | 7 |
| Osteonecrosis | 5 |
| Fractures, Bone | 2 |
| Ankle Fractures | 1 |
Showing 5 of 15 disease areas.
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2021 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2015 | 1 |
| 2012 | 3 |
| 2011 | 1 |
| 2010 | 1 |
| 2009 | 3 |
| 2008 | 3 |
Showing 10 of 15 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 4 hit target (n=4) | 1 of 3 on time (n=3) |
Journals published in (8)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of bone and joint surgery. American volume | 2 |
| The spine journal : official journal of the North American Spine Society | 2 |
| American journal of orthopedics (Belle Mead, N.J.) | 1 |
| Archives of orthopaedic and traumatic surgery. Archiv fur orthopadische und Unfall-Chirurgie | 1 |
| Archives of physical medicine and rehabilitation | 1 |
Showing 5 of 8 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 67 | 31 | 2025-10-14 |
Financing and grant events (3)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-15 | IPO | 18,630,000 | Edgar offerings |
| 2022-04-21 | Private placement | 1,080,000 | Form d |
| 2020-12-07 | Private placement | 250,000 | Form d |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 8 |
FDA recalls (99)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Brand Name: EMPOWR 3D KNEE Product Name: EMPOWR 3D KNEE INS, 11L 14MM, VE Model/Catalog Number: 342-19-703 Product Description: Enovis knee devices are intended for knee arthroplasty. | Class II | 2026-02-16 |
| Brand Name: EMPOWR 3D KNEE Product Name: EMPOWR 3D KNEE INS, 11L 14MM, VE Model/Catalog Number: 341-14-711 Product Description: Enovis knee devices are for knee arthroplasty. | Class II | 2026-02-16 |
| Brand Name: Reverse Shoulder Prosthesis (RSP) Product Name: RSP HUMERAL SOCKET INSERT, 32MM +4MM, STANDARD HXe-plus Model/Catalog Number: 509-00-432 | Class II | 2026-01-15 |
| Brand Name: EMPOWR 3D KNEE Product Name: EMPOWR 3D KNEE INS, 7L 16MM, VE Model/Catalog Number: 341-16-707 | Class II | 2026-01-15 |
| Brand Name: Reverse Shoulder Prosthesis (RSP) Product Name: RSP STANDARD HUMERAL SOCKET INSERT, 36MM, HXe-plus Model/Catalog Number: 509-00-036 | Class II | 2026-01-15 |
Showing 5 of 99 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2025-09-02 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| ENCORE MEDICAL, L.P. | AUSTIN, US | FDA |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Bright Research Partners (United States) | Co sponsors trial with | 1 |
| Yale Cardiovascular Research Group | Co sponsors trial with | 1 |
Latest dated events (201)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-02-16 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-02-16 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-01-15 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-01-15 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-01-15 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 201 events.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.